NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support 12 Oct 2016 (#35)

[Click on blue hyperlink for further information]

*The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.*

*Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa Coetsee cdevries@sun.ac.za) **as soon as possible to inform of your intent to apply and then confirm at least 30 days before the submission date**. The NIH grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.***

Important notices

- **Optional Electronic Submission Method to Request to Submit an Unsolicited Application That Will Exceed $500,000 In Direct Costs (NOT-OD-17-005).** This notice informs NIH applicants that requests to submit an unsolicited application that will exceed $500,000 in direct costs will now have an option to submit this request electronically through eRA Commons, under a new Prior Approval Module.
- **Notice of Clarification of the Purpose and Research Objectives and Revised Research Strategy Instructions in PAR-16-115 "Optimization of Monoclonal Antibodies for Eliminating the HIV Reservoir (R01)" (NOT-AI-16-087)**

1. Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Tuberculosis Disease

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (RFA-AI-16-079) **Type: R01**

Application Due Date: March 2, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on establishing proof-of-concept for and/or preclinical development of lead candidate vaccines targeting infection with Mycobacterium tuberculosis (Mtb) and/or tuberculosis disease (TB).

Budget: NIAID intends to commit $6.2 million in FY 2018 to fund 5-10 awards. Budgets for direct costs of up to $750,000 per year may be requested. Applicants may also request up to an additional $300,000 in direct costs in the first year of the award for major equipment to ensure that research objectives can be met and biohazards can be contained, totaling $1,050,000 direct costs. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. Collaborative Consortia for the Study of HIV Associated Cancers: U.S. and Low-and Middle-Income Country Partnerships

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (RFA-CA-16-018) **Type: U54**

Application Due Date: December 20, 2016Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to fund research on HIV-associated cancers in low- and middle-income countries (LMICs) through collaborative efforts between investigators in United States (U.S.) and investigators in LMICs. The FOA will also support the enhancement of research capacity of LMIC institutions for research in this area. The FOA solicits applications for Specialized Center Cooperative Agreements (U54) for research on HIV-associated cancers from research institutions in the U.S. and LMICs. Each application is required to propose between two to three research projects that address high-priority questions relevant to both the LMIC and the NIH HIV/AIDS research agenda. The proposed projects may range, as appropriate, from basic research to translational efforts as well as population and implementation studies. Clinical trials, however, will not be supported. In addition, the proposed consortium must include two mandatory cores; an Administrative Core and a Career Enhancement Core. Additional cores such as Shared Resource cores may be included as appropriate for the needs of the projects.

Budget: The NCI and FIC intend to commit an estimated total amount of 2.4 million dollars in Fiscal Year 2017 to fund 2-3 awards. Application budgets should be commensurate with the scope of the research activities proposed but must not exceed $600,000 per year in direct costs. Applicants may request up to five years of support.

3. Emerging Global Leader Award

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (PAR-17-001) **Type: K43**

Application Due Date: December 14, 2016; December 14, 2017; and December 13, 2018Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: The purpose of the Fogarty Emerging Global Leader Award is to provide research support and protected time (three to five years) to an early career research scientist from a low- or middle-income country (LMIC) who holds a junior faculty position at an LMIC academic or research institution, as defined by the World Bank (http://data.worldbank.org/about/country-classifications/country-and-lending-groups, including "low-income," "lower-middle-income," and "upper-middle-income" countries). This intensive, mentored research career development experience is expected to lead to an independently funded research career at the LMIC institution or in another LMIC. This Funding Opportunity Announcement (FOA) invites applications from LMIC scientists from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of their country under the mentorship of LMIC and U.S. mentors.

Budget: NIH will contribute up to $ 75,000 (for a minimum of 75% effort or 9 person months) per year toward the salary of the career award recipient. NIH will contribute up to $ 30,000 per year toward the research development costs of the award recipient, which must be justified and consistent with the stage of development of the candidate and the proportion of time to be spent in research or career development activities.

4. Secondary Analyses of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (PAR-17-004) **Type: R21**

Application Due Date: February 24, 2017; February 23, 2018; February 22, 2019Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: The goal of this funding opportunity is to stimulate the use of existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the NHLBI mission. This FOA actively supports the use of existing database resources to conduct additional analyses secondary to a project's originally-intended primary purpose. Applications may be related to, but must be distinct from, the specific aims of the original data collection; it will not support the collection of new data.

Budget: Direct costs must be limited to $150,000 over a R21 two-year period, with no more than $75,000 in direct costs allowed in any single year. The total project period may not exceed 2 years.

5. In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability

Letter of Intent due date: 30 days prior to the application due date **Hyperlink:** (PAR-17-005) **Type: R01**

Application Due Date: June 5, 2017; October 5, 2017. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. ***Applicants should be aware that on-time submission means that an application is submitted error free*** (to both Grants.gov and eRA Commons) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. The KOMP2 KO mouse phenotyping effort has generated 2,500 mouse strains with plans to generate an additional 6,000 over the next five years. Overall, the IMPC hopes to achieve broad-based phenotyping of 20,000 KO strains. About 30% of these strains either are or are expected to be embryonic or perinatal lethal or subviable. A large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes. The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in depth phenotyping and research.

Budget: Budgets with direct costs of up to $499,999 per year may be requested. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Brief definitions of some NIH grant mechanisms: *comprehensive list of extramural grant and cooperative agreement activity codes*

D71 - International Research Training Planning Grant: To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

D43 - International Research Training Grants: To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <$50,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

R25 – NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R34 - Clinical Trial Planning Grant Program: To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

R35 - Outstanding Investigator Award: To provide long term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U19 - **Research Program-Cooperative Agreements:** supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.

Glossary of selected acronyms:

FOA Funding Opportunity Announcement

PA Program Announcements *(click on "PA" to search for further funding opportunities)*

RFA Request for Applications *(click on "RFA" to search for further funding opportunities)*

Complete Glossary and acronym list of NIH Terms

NIH National Institutes of Health
Turning Discovery Into Health

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: ***Dr Christa Coetsee*** • Tel: 9838 • Email: **cdevries@sun.ac.za**